Sperogenix Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series B

  • Investors
  • 4

Sperogenix Therapeutics General Information

Description

Operator of a platform and developer of treatments for rare and underserved medical conditions intended for therapeutic use. The company provides clinical development, customer communication, and business expansion services to medical businesses at the late clinical stage and commercialization stage, enabling clients to bring benefits to millions of people with rare diseases in China.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Building A, Innovation Park
  • Number 56 Dongzhimenwai Xiejie, Chaoyang District
  • Beijing, 100027
  • China
+86 010
Primary Industry
Enterprise Systems (Healthcare)
Other Industries
Other Healthcare Services
Biotechnology
Vertical(s)
Corporate Office
  • Building A, Innovation Park
  • Number 56 Dongzhimenwai Xiejie, Chaoyang District
  • Beijing, 100027
  • China
+86 010

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sperogenix Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B) 23-Oct-2023 Completed Generating Revenue
2. Later Stage VC (Series A1) 31-Dec-2021 Completed Generating Revenue
1. Early Stage VC (Series A) 10-May-2019 Completed Generating Revenue
To view Sperogenix Therapeutics’s complete valuation and funding history, request access »

Sperogenix Therapeutics Patents

Sperogenix Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4532492-A1 Nitrogen-containing five-membered heterocyclic derivatives as checkpoint kinase 1 inhibitor and uses thereof Pending 25-May-2022
EP-4532492-A4 Nitrogen-containing five-membered heterocyclic derivatives as checkpoint kinase 1 inhibitor and uses thereof Pending 25-May-2022
US-20250346587-A1 Nitrogen-containing five-membered heterocyclic derivatives as checkpoint kinase 1 inhibitor and uses thereof Pending 25-May-2022
WO-2023226658-A1 Nitrogen-containing five-membered heterocyclic derivatives as checkpoint kinase 1 inhibitor and uses thereof Inactive 25-May-2022
EP-4298095-A1 Heterocyclic compounds as kinase inhibitor and uses thereof Pending 30-Jan-2021 C07D403/12
To view Sperogenix Therapeutics’s complete patent history, request access »

Sperogenix Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Jiangsu Dingxin Capital Management Venture Capital Minority
Prosperico Ventures Venture Capital Minority
5Y Capital Venture Capital Minority
LAV (Lilly Asia Fund) Corporate Venture Capital Minority
To view Sperogenix Therapeutics’s complete investors history, request access »

Sperogenix Therapeutics FAQs

  • When was Sperogenix Therapeutics founded?

    Sperogenix Therapeutics was founded in 2015.

  • Where is Sperogenix Therapeutics headquartered?

    Sperogenix Therapeutics is headquartered in Beijing, China.

  • What industry is Sperogenix Therapeutics in?

    Sperogenix Therapeutics’s primary industry is Enterprise Systems (Healthcare).

  • Is Sperogenix Therapeutics a private or public company?

    Sperogenix Therapeutics is a Private company.

  • What is Sperogenix Therapeutics’s current revenue?

    The current revenue for Sperogenix Therapeutics is .

  • How much funding has Sperogenix Therapeutics raised over time?

    Sperogenix Therapeutics has raised $30M.

  • Who are Sperogenix Therapeutics’s investors?

    Jiangsu Dingxin Capital Management, Prosperico Ventures, 5Y Capital, and LAV (Lilly Asia Fund) have invested in Sperogenix Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process